Ferroptosis: Redox Imbalance and Hematological Tumorigenesis
Open Access
- 26 January 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 834681
- https://doi.org/10.3389/fonc.2022.834681
Abstract
Ferroptosis is a novel characterized form of cell death featured with iron-dependent lipid peroxidation, which is distinct from any known programmed cell death in the biological processes and morphological characteristics. Recent evidence points out that ferroptosis is correlated with numerous metabolic pathways, including iron homeostasis, lipid metabolism, and redox homeostasis, associating with the occurrence and treatment of hematological malignancies, such as multiple myeloma, leukemia, and lymphoma. Nowadays, utilizing ferroptosis as the target to prevent and treat hematological malignancies has become an active and challenging topic of research, and the regulatory network and physiological function of ferroptosis also need to be further elucidated. This review will summarize the recent progress in the molecular regulation of ferroptosis and the physiological roles and therapeutic potential of ferroptosis as the target in hematological malignancies.This publication has 113 references indexed in Scilit:
- Loss of the Tumor Suppressor BAP1 Causes Myeloid TransformationScience, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Ferritin Protein Nanocage Ion ChannelsOnline Journal of Public Health Informatics, 2012
- The oxidative stress-inducible cystine/glutamate antiporter, system x c − : cystine supplier and beyondAmino Acids, 2011
- Multiple myelomaBlood, 2008
- Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversityProceedings of the National Academy of Sciences of the United States of America, 2008
- Vitamin E, antioxidant and nothing moreFree Radical Biology & Medicine, 2007
- The role of iron regulatory proteins in mammalian iron homeostasis and diseaseNature Chemical Biology, 2006
- Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questionsBlood, 2006
- PROGRAMMED CELL DEATH: CONCEPT, MECHANISM AND CONTROLBiological Reviews, 1992